The Manufacturing, Materials and Minerals Group contains the core of CSIRO’s research focus in the materials, manufacturing, minerals, mining, chemicals, health and infrastructure sectors.
An international recognised expert in medical imaging Dr Simon K. Warfield, has been awarded an Australia-Harvard Fellowship to travel to Australia to work closely with the biomedical imaging team at the Australian e-Health Research Centre on early diagnosis of Alzheimer’s disease.
CSIRO has entered into an agreement with Adelaide-based biotech company, Oncaidia Ltd, to make the company’s new anti-cancer drug, Apomab®, suitable for human trials.
An exciting conference that will bring together international world leaders in polymer sciences and industry leaders to share perspectives and work towards producing superior products for the marketplace into the future.
Using nanotechnology and conductive polymers to develop a new generation of plastic electronics that will change our lives in much the same way as the first microchip did.
CSIRO can develop new, composite materials to improve the design and fabrication of products, and introduce new qualities such as lightness and corrosion resistance.
This video discusses the winning of a CSIRO Medal for Research Achievement 2006 by Dr Colin Ward and his team for the development of the insulin receptor. (2:30)
This video looks at how CSIRO solved the structure of a flu virus surface protein and led the development of the first anti-viral flu drug effective against all strains of flu. (3:00)
Dr Megan Fisher is acting Chief of CSIRO Molecular and Health Technologies, she has tertiary qualifications in science and business and an outstanding track record in strategic management, business development and technology commercialisation.
A list of RAFT (reverse addition fragmentation chain transfer) patents, their backgrounds, advantages of the invention and application areas. (7 pages)
A one-page information sheet with details of the 9th Protein Expression Workshop that will cover a range of topics to enable successful production of proteins.
CSIRO’s IP is a platform technology for the rapid expansion of cells whilst maintaining phenotype. The technology will be useful for a wide range of cellular therapies and tissue engineering applications. (2 pages)
